J.P. Morgan upgrades Protagonist to overweight following clinical hold removal

Oct. 12, 2021 8:33 AM ETProtagonist Therapeutics, Inc. (PTGX)By: Jonathan Block, SA News Editor

JP Morgan Chase and Co

subman/iStock Unreleased via Getty Images

  • J.P. Morgan has upgraded Protagonist Therapeutics (NASDAQ:PTGX) from neutral to overweight after the FDA removed a clinical hold on its clinical studies for rusfertide.
  • The firm also upped its price target to $55 from $49 (~56% upside).

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.